FDA 483 - Similasan AG - April 27, 2026

Similasan AG, a homeopathic pharmaceutical manufacturer in Ittigen, Switzerland, was inspected by the FDA, revealing significant deficiencies. The observations primarily concern inadequate quality control for components, insufficient process validation, and poor equipment control and in-process checks. These issues indicate a lack of robust controls to ensure drug product quality and consistency.